Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators. Lin C, et al. Among authors: tripathy d. Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28. Breast Cancer Res Treat. 2012. PMID: 21796368 Free PMC article.
Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Lang JE, et al. Among authors: tripathy d. Breast Cancer Res Treat. 2015 Jan;149(1):121-31. doi: 10.1007/s10549-014-3215-0. Epub 2014 Nov 29. Breast Cancer Res Treat. 2015. PMID: 25432738 Free PMC article. Clinical Trial.
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF. Sharma P, et al. Among authors: tripathy d. Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821. Ann Oncol. 2018. PMID: 29293876 Free PMC article. Clinical Trial.
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.
Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Yamauchi T, et al. Among authors: tripathy d. Oncotarget. 2018 Jan 4;9(6):6872-6882. doi: 10.18632/oncotarget.23914. eCollection 2018 Jan 23. Oncotarget. 2018. PMID: 29467936 Free PMC article.
743 results